Autistic Disorders and Medical Biotechnology

en 25926945 Autistic Disorders and Medical Biotechnology Autistic Disorders (ADs) are neuro-developmental disorders in the category of pervasive developmental disorders chiefly described by three main deficits: 1) deviant communication, 2) impaired reciprocal social interaction, and 3) limited, repetitive and stereotypic patterns of behaviors or interests 1. The world-wide prevalence of ADs is estimated to be 62/10,000 1. Although various treatment regimens have been proposed for improving overall function of autistic patients, a definite efficient treatment which can target both core and associated symptoms in ADs has not been established so far. For example, current approved drugs by the Food and Drug Administration (FDA) such as risperidone and aripiprazole have not been proven to pose significant effect on the core features of this disorder 2-4. While the absolute pathophysiologic mechanism of ADs is still debated, several genetic, environmental and neurobiological factors such as immune dysfunction, oxidative stress and imbalance of the inhibitory-excitatory systems are implicated in the pathogenesis of these disorders 5-7. Neurobiological models have become research areas of interest for development of novel therapeutic agents in this regard 1. Increased neuronal excitation in various central pathways has been proposed as one of the main neurobiological dysregulations in autistic patients 1. Indeed, biotechnology and in particular gene therapies plays an important role in the future of research in autism 1. Neurexin 1: Part of family of genes that play a role with the neurotransmitter glutamate which is linked to autism. Gene chip technology was used to scan for genetic similarities in people with autism. DNA was scanned to search for copy number variations (CNVs), or insertions and deletions of genetic material linked to autism 1. Adult Form of Fragile X Syndrome: Expression of toxic RNA leads to Fragile X Tremor Ataxia Syndrome is modifiable by gene therapy 1. Fragile X Syndrome: Caused by loss of a gene called FMPR which acts as a break on a protein synthesis in specific area of the brain. This allows another protein, mGluR5 Metabotropic Glutamate Receptor, to function unchecked resulting in over activity in the brain. Reducing mGluR5 reduces symptoms associated with fragile x syndrome 1. MECP2 Activation of the gene reversed Rett syndrome. The MECP2 gene mutation is present in 95 percent of individuals with the disease 1. Autistic disorder, Biotechnology, Genetic diseases 1 1 https://www.ajmb.org/En/Article.aspx?id=193 https://www.ajmb.org/PDF/En/FullText/193.pdf ShahinAkhondzadehTehran University of Medical Sciences, Tehran, Iran739

en 25926946 Production and Characterization of Monoclonal Antibodies against Human Prostate Specific Antigen Background: Prostate Specific Antigen (PSA) is an important laboratory marker for diagnosis of prostatic cancer. Thus, development of diagnostic tools specific for PSA plays an important role in screening, monitoring and early diagnosis of prostate cancer. In this paper, the production and characterization of a panel of murine monoclonal antibodies (mAbs) against PSA have been presented.  Methods: Balb/c mice were immunized with PSA, which was purified from seminal plasma. Splenocytes of hyperimmunized mice were extracted and fused with Sp2/0 cells. By adding selective HAT medium, hybridoma cells were established and positive clones were selected by ELISA after four times of cloning. The isotypes of produced mAbs were determined by ELISA and then purified from ascitic fluids using Hi-Trap protein G column. The reactivities of the mAbs were examined with the purified PSA and seminal plasma by ELISA and western blot techniques. Furthermore, the reactivities of the mAbs were assessed in Prostate Cancer (PCa), Benign Prostatic Hyperplasia (BPH) and brain cancer tissues by Immunohistochemistry (IHC). Results: Five anti-PSA mAbs (clones: 2G2-B2, 2F9-F4, 2D6-E8, IgG1/К) and clones (2C8-E9, 2G3-E2, IgG2a/К) were produced and characterized. All mAbs, except 2F9-F4 detected the expression of PSA in PCa and BPH tissues and none of them reacted with PSA in brain cancer tissue in IHC. Besides, all mAbs could detect a protein band around 33 kDa in human seminal plasma in western blot. Conclusion: These mAbs can specifically recognize PSA and may serve as a component of PSA diagnostic kit in various biological fluids. ELISA, Immunohistochemistry, Monoclonal antibody, Prostate specific antigen, Western blot 2 7 https://www.ajmb.org/En/Article.aspx?id=194 https://www.ajmb.org/PDF/En/FullText/194.pdf Ali AhmadBayat Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran835RoyaGhodsDepartment of Molecular Medicine, School of Advanced Medical Technologies, Tehran University of Medical Sciences, Tehran, Iran8MahdiShabaniMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran125Ahmad RezaMahmoudiMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran33OmidYeganehMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran600HadiHassanniaDepartment of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran836AliSadeghitabarMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran837LeilaBalay-GoliMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran838FarzanehNoutash-HaghighatMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran839Ali rezaSarrafzadehDepartment of Pathology, Khatam Al Anbia Hospital, Tehran, Iran840MahmoodJeddi-TehraniMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran15

en 25926947 Comparative Analysis of Prostate Cancer Gene Regulatory Networks via Hub Type Variation Background: Prostate cancer is one of the most widespread cancers in men and is fundamentally a genetic disease. Identifying regulators in cancer using novel systems biology approaches will potentially lead to new insight into this disease. It was sought to address this by inferring gene regulatory networks (GRNs). Moreover, dynamical analysis of GRNs can explain how regulators change among different conditions, such as cancer subtypes. Methods: In our approach, independent gene regulatory networks from each prostate state were reconstructed using one of the current state-of-art reverse engineering approaches. Next, crucial genes involved in this cancer were highlighted by analyzing each network individually and also in comparison with each other. Results: In this paper, a novel network-based approach was introduced to find critical transcription factors involved in prostate cancer. The results led to detection of 38 essential transcription factors based on hub type variation. Additionally, experimental evidence was found for 29 of them as well as 9 new transcription factors. Conclusion: The results showed that dynamical analysis of biological networks may provide useful information to gain better understanding of the cell. Gene regulatory networks, Prostate cancer, Transcription factors 8 15 https://www.ajmb.org/En/Article.aspx?id=195 https://www.ajmb.org/PDF/En/FullText/195.pdf PegahKhosraviSchool of Biological Sciences, Institute for Research in Fundamental Sciences (IPM), Tehran, Iran841Vahid H.GazestaniInstitute of Parasitology, McGill University, Montreal , Quebec, Canada842MohammadAkbarzadehDepartment of Bioinformatics, Institute of Biochemistry and Biophysics (IBB), University of Tehran, Tehran, Iran843SamiraMirkhalaf Department of Bioinformatics, Institute of Biochemistry and Biophysics (IBB), University of Tehran, Tehran, Iran844MehdiSadeghiNational Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran846BahramGoliaeiDepartment of Bioinformatics, Institute of Biochemistry and Biophysics (IBB), University of Tehran, Tehran, Iran845

en 25926948 Effects of Combined Soy Isoflavone Extract and Docetaxel Treatment on Murine 4T1 Breast Tumor Model Background: Emergence of drug resistance has brought major problems in chemotherapy. Using nutrients in combination with chemotherapy could be beneficial for improvement of sensitivity of tumors to drug resistance. Soybean-derived isoflavones have been suggested as chemopreventive agents for certain types of cancer, particularly breast cancer. In this study, the synergistic effects of soy isoflavone extract in combination with docetaxel in murine 4T1 breast tumor model were investigated. Methods: In this study, mice were divided into 4 groups (15 mice per group) of control, the dietary Soy Isoflavone Extract (SIE, 100 mg/kg diet), the Docetaxel (DOCE, 10 mg/kg) injection and the combination of dietary soy isoflavone extract and intravenous docetaxel injection (DOCE+SIE). After 3 injections of docetaxel (once a week), 7 mice were sacrificed to analyze MKI67 gene and protein expressions and the rest were monitored for diet consumption, tumor growth and survival rates. Results: In DOCE+SIE group, diet consumption was significantly higher than DOCE group. While lifespan showed a trend towards improvement in DOCE+SIE group, no significant difference was observed among the 4 studied groups. Tumor volume was not significantly affected in treated groups. A lower but not significant MKI67 protein expression was detected in western blot in DOCE+SIE group. The mRNA expression was not significantly different among groups. Conclusion: The results suggest that the combination of soy isoflavone as an adjunct to docetaxel chemotherapy can be effective in improving diet consumption in breast cancer. Breast cancer, Docetaxel, Soy isoflavone extract 16 21 https://www.ajmb.org/En/Article.aspx?id=196 https://www.ajmb.org/PDF/En/FullText/196.pdf EhsanHejaziDepartment of Clinical Nutrition and Dietetics, School of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran847JavadNasrollahzadeh Department of Clinical Nutrition and Dietetics, School of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran848RaminaFatemiReproductive Immunology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran849LeilaBarzegar-Yar MohamadIMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran850KioomarsSaliminejadReproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran393ZohreAmiriDepartment of Basic Sciences and Cellular and Molecular Nutrition, School of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran851MasoudKimiagarDepartment of Clinical Nutrition and Dietetics, School of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran852MohammadHoushyariDepartment of Radiation Oncology, Shohada Tajrish Hospital, Shahid Beheshti University of Medical Science, Tehran, Iran853MaryamTavakoliReproductive Immunology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran854FarahIdaliReproductive Immunology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran855

en 25926949 Intravenous Transplantation of Very Small Embryonic Like Stem Cells in Treatment of Diabetes Mellitus Background: Diabetes Mellitus (DM), simply known as diabetes, refers to a group of metabolic diseases in which there are high blood sugar levels over a prolonged period. In this study, the feasibility and safety of intravenous transplantation of Very Small Embryonic Like stem cells (VSELs) were investigated for diabetes repair, and finally the migration and distribution of these cells in hosts were observed. Methods: Mouse bone marrow VSELs were isolated by Fluorescent Activating Cell Sorting (FACS) method by using fluorescent antibodies against CD45, CXCR4 and Sca1 markers. Sorted cells were analyzed for expression of oct4 and SSEA1 markers with immunocytochemistry staining method. To determine multilineage differentiation, sorted cells were differentiated to Schwann, osteocyte and beta cells. Ten days after the establishment of a mouse model of pancreas necrosis, DiI-labeled VSELs were injected into these mice via tail vein. Pancreases were harvested 4 weeks after transplantation and the sections of these tissues were observed under fluorescent microscope. Results: It was proved that CD45-, CXCR4+, and Sca1+ sorted cells express oct4 and SSEA1. Our results revealed that intravenously implanted VSELs could migrate into the pancreas of hosts and survive in the diabetic pancreas. In treated groups, blood glucose decreased significantly for at least two month and the weights of mice increased gradually.   <div> Conclusion: This study provides a strategy for using VSELs for curing diabetes and other regenerative diseases, and the strategy is considered an alternative for other stem cell types. </div> Diabetes mellitus, Transplantation, Very small embryonic like stem cells 22 31 https://www.ajmb.org/En/Article.aspx?id=197 https://www.ajmb.org/PDF/En/FullText/197.pdf MorteazAbouzaripourFaculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran722IrajRagerdi KashaniFaculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran716ParichehrPasbakhshFaculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran858NaderAtlasyFaculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran859

en 25926950 ADSCs on PLLA/PCL Hybrid Nanoscaffold and Gelatin Modification: Cytocompatibility and Mechanical Properties Background: Development of tissue engineering and regenerative medicine has led to designing scaffolds and their modification to provide a better microenvironment which mimics the natural niche of the cells. Gelatin surface modification was applied to improve scaffold flexibility and cytocompatibility. Methods: PLLA/PCL aligned fibrous scaffold was fabricated using electrospinning method. ADSCs were seeded after O2 plasma treatment and gelatin coating of the scaffolds. The morphological and mechanical properties of blends were assessed by Scanning Electron Microscopy (SEM), tensile test and ATR-FTIR. The cells proliferation was evaluated by MTT assay.  Results: Based on the results, it is supposed that gelatin coating is a brilliant method of surface modification which significantly increases the mechanical properties of scaffold without any changes on the construction or on the direction of nanofibers which conducts cell’s elongation. MTT analysis exhibited that ADSCs attachment, viability and proliferation significantly (p<0.05) increased after gelatin treatment. Conclusion: Gelatin surface modification is a highly beneficial method to improve cytocompatibility, flexibility and mechanical features of the scaffolds which doesn’t affect the nanofibers construction. Proliferation of Adipose Derived Stem Cells (ADSCs) as a remarkable source of stem cells was investigated for the first time on PLLA/PCL hybrid scaffold. Gelatin, Tissue engineering, Tissue scaffold 32 38 https://www.ajmb.org/En/Article.aspx?id=198 https://www.ajmb.org/PDF/En/FullText/198.pdf MaedehMashhadikhan Department of Biology, Faculty of Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran860MasoudSoleimaniDepartment of Hematology and Blood Banking, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran221KazemParivar Department of Biology, Faculty of Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran862MarjanYaghmaeiDepartment of Biology, Faculty of Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran373

en 25926951 Cloning and Expression of CD19, a Human B-Cell Marker in NIH-3T3 Cell Line Background: CD19 is a pan B cell marker that is recognized as an attractive target for antibody-based therapy of B-cell disorders including autoimmune disease and hematological malignancies. The object of this study was to stably express the human CD19 antigen in the murine NIH-3T3 cell line aimed to be used as an immunogen in our future study. Methods: Total RNA was extracted from Raji cells in which high expression of CD19 was confirmed by flow cytometry. Synthesized cDNA was used for CD19 gene amplification by conventional PCR method using Pfu DNA polymerase. PCR product was ligated to pGEM-T Easy vector and ligation mixture was transformed to DH5α competent bacteria. After blue/white selection, one positive white colony was subjected to plasmid extraction and direct sequencing. Then, CD19 cDNA was sub-cloned into pCMV6-Neo expression vector by double digestion using KpnI and HindIII enzymes. NIH-3T3 mouse fibroblast cell line was subsequently transfected by the construct using Jet-PEI transfection reagent. After 48 hours, surface expression of CD19 was confirmed by flow cytometry and stably transfected cells were selected by G418 antibiotic. Results: Amplification of CD19 cDNA gave rise to 1701 bp amplicon confirmed by alignment to reference sequence in NCBI database. Flow cytometric analysis showed successful transient and stable expression of CD19 on NIH-3T3 cells (29 and 93%, respectively). Conclusion: Stable cell surface expression of human CD19 antigen in a murine NIH-3T3 cell line may develop a proper immunogene which raises specific anti-CD19 antibody production in the mice immunized sera. B cell, CD19, Cloning, Gene expression 39 44 https://www.ajmb.org/En/Article.aspx?id=199 https://www.ajmb.org/PDF/En/FullText/199.pdf HajarAbbasi-KenarsariStudents Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran866FarzanehShafaghatDepartment of Immunology, International Branch of Aras, Tabriz University of Medical Sciences, Tabriz, Iran867BehzadBaradaranDepartment of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran868Ali AkbarMovassaghpourHematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran869DariushShanehbandiImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran872TohidKazemiDepartment of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran871

en 25926952 Use of Raman Spectroscopy to Decrease Time for Identifying the Species of Candida Growth in Cultures Background: The objective of this study is to establish Raman signatures from pure cultures of different Candida species using Raman Spectroscopy (RS) and use these signatures for rapid identification of unknown Candida species. Methods: Pure cultures of five Candida species were evaluated using RS to build a limited signature library. ‘Raman Processing’ (RP) software was used for Principal Component Analysis (PCA) and Differential Functional Analysis (DFA). Results: Eleven principal components described at least 95% variance in the spectra. Raman signatures from these known Candida species were able to identify the species of unknown Candida cultures with 100% accuracy. Conclusion: Raman spectroscopy can improve early identification of Candida species and may facilitate early optimal antifungal therapy.   Candida species, Raman, Spectrum analysis 45 48 https://www.ajmb.org/En/Article.aspx?id=200 https://www.ajmb.org/PDF/En/FullText/200.pdf NitinS. ChouthaiDivision of Neonatal-Perinatal Medicine, Wayne State University , Detroit, MI, , United States of America874AnujA. Shah Division of Neonatal-Perinatal Medicine, Wayne State University, Detroit, MI, United States of America875HosseinSalimniaDivision of Pathology, Wayne State University, Detroit, MI, United States of America876OlenaPalyvoda Lumigen Instrument Center, Wayne State University, Detroit, MI, United States of America877SuneethaDevpura Department of Radiation Oncology, Henry Ford Health System, Detroit MI, United States of America878MichaelKlein Pediatric Surgery, Wayne State University , Detroit, MI, United States of America879BasimAsmar Division of Pediatric Infectious Diseases, Wayne State University , Detroit, MI, United States of America 880